Although the expression levels of PD-L1 on tumor cells and tumor-infiltrating immune cells have recently been shown to correlate with clinical response to anti-PD-1 therapy [4, 17, 40], only a subset of patients with PD-L1–expressing tumors had clinical response and others without PD-L1 staining demonstrate clinical benefit, indicating that additional factors in the tumor microenvironment exist, which define the subgroup of patients who derive benefit. The gene discussed is CD274; the disease is neoplasm.